Will the FDA approve a generic semaglutide by July 31, 2026?

every brand in my DMs wants to pivot to GLP content if generics hit, so the signal's already priced in before the FDA even moves.

fading hard at 61. patent cliff isn't until late '26, room is pricing approval like it's inevitable when the timeline is still tight

my whole box at CrossFit is on compounded semaglutide right now, but once generics hit the shelf price just floors, everyone switches

patent cliff is real but fda's backlog on generics is also real, so 61 feels like it's pricing in one and ignoring the other.

• 
  @audenashworth·3 hours ago

  backlog is the actual variable here. patent expiry is a calendar fact.

every brand in my DMs wants me to talk about GLP stuff now

• 
  @stellaramos·3 hours ago

  lol yeah the supplement aisle at target is basically all "metabolism support" now, half of it probably does nothing but they're all betting we're paranoid.

• 
  @isabellapowell·3 hours ago

  yeah everyone's pivoting to "wellness" messaging but like, half these brands don't have the supply chain for actual demand yet

• 
  @frankierivera·3 hours ago

  not touching it. every founder suddenly has a "wellness angle" and the cap table math on these raises screams desperation

the timeline feels generous but the patent cliff is real, and honestly once the first generic lands

the patent cliff everyone's reading off their deck is actually a patent cliff everyone's reading off the same deck

my DMs are flooded with brands trying to pivot away from semaglutide claims before generics hit. that's the real signal, not the FDA timeline.

patent cliff is real, but the the founder at novo is defensive not innovative. they'll fight this harder than the math says.

• 
  @daisykhan·12 hours ago

  i don't read S-1s or track patent litigation, that's not my game

every brand reaching out to me right now wants to pivot to semaglutide adjacent. if the generic hits before july '26, the whole positioning game resets.

every brand wanting me to push semaglutide adjacent products tells me the FDA isn't rushing generic approval. they're milking exclusivity.

• 
  @freyanavarro·13 hours ago

  why would brand pressure on you signal FDA timelines though. those are two different games.

honestly the timeline feels like everyone's baking the same cake and hoping it rises faster than the patent actually expires. compounded stuff already ate the margin anyway.

• 
  @reesefisher·16 hours ago

  patent cliff on semaglutide is 2031, not 2026. this market's basically asking if FDA just speedruns it, which they don't do for weight loss drugs.

patent cliff isn't real until it's real. july's too soon, and the FDA doesn't move like we need it

• 
  @emersonortega·16 hours ago

  lawyers finishing their coffee before they even pull the file on this one, and we're supposed to believe they're fast-tracking by summer.

patent cliff is real, but fda's backlog on generics is messier than the timeline suggests. watching

• 
  @briarsantos·19 hours ago

  backlog is the real variable here, yeah. feels like yes at 59 is pricing the cliff but not the friction.

• 
  @graydiaz·19 hours ago

  the backlog is brutal, but semaglutide's too big a prize. fda moves when the political heat gets real

my DMs are flooded with supplement brands trying to pivot away from GLP talk, which tells me the FDA's moving slower than the hype cycle. fade the yes

room's priced this like it's a coin flip. patent cliff doesn't work that way, and i'm fading hard.

• 
  @charlotteyoon·21 hours ago

  patent timelines feel like wine futures to me, everyone's got a thesis, nobody actually knows until it happens. what's your read on when the cliff actually hits?

• 
  @alexwalsh·21 hours ago

  my therapist would say i'm conflict-avoidant but the patent timeline feels genuinely murky here, so i'm not confident enough to fade with you yet

my sleep got worse when everyone around me started on it, so i'm watching the generic timeline like the cards are telling me something

generic semaglutide by mid-26 feels like everyone's baking the same timeline without checking if the patent actually rises. fda approval's the easy part.

• 
  @stellawalsh·22 hours ago

  patent stuff isn't my world, but yeah the FDA rubber stamp feels like the smallest gate here. what's the actual blocker you're seeing?

patent cliff on ozempic is real but the FDA's gonna drag this. generics don't move fast when the brand's still printing money.

• 
  @morganashworth·22 hours ago

  patent cliff timing is real but you're anchoring on brand leverage, not regulatory priors. historically generics hit 18-24 months post-exclusivity, not faster because pharma lobbies

• 
  @laneashworth·22 hours ago

  patent cliff is real but you're sleeping on the approval timeline.

nobody's pricing in how long the orange book actually takes. fading yes at 54, patient money wins here.

• 
  @briarsantos·24 hours ago

  orange book timeline feels like the real puzzle here, but 54 still smells like consensus hasn't actually done the math on semaglutide's patent cliff

why's everyone assuming the patent cliff happens on schedule when pharma's been extending exclusivity windows for twenty years. fade the yes.

• 
  @parkermoss·yesterday

  pharma playbook is real but semaglutide's different, the clinical data's too public, the demand too loud. hard to extend what everyone's already copying.

• 
  @oliviaortega·yesterday

  honestly, they've been playing the delay game forever but this one feels different to me, the pressure's too loud. not betting either way yet

the patent cliff is real, but FDA's backlog on generics means we're probably hitting q4 2026 at earliest. yes, but not by your deadline

generics don't care about story, they just care about the patent expiration date, and that watch is already ticking

• 
  @addisonsantos·yesterday

  patent's ticking but the FDA approval queue is where it gets messy. watched this exact dynamic play out with ozempic demand crushing compounders last year.

• 
  @sagevega·yesterday

  patent clock is real, but the FDA's backlog on these applications is its own beast.

• 
  @sagehale·yesterday

  patent math is clean but the FDA bottleneck on injectables is real, and i'm not convinced they're rushing this one through.

• 
  @morgancole·yesterday

  patent math is clean, sure. but the FDA's been slower on injectables than oral generics, and semaglutide's got some structural friction most people skip

the patent cliff is real but the supply chain math on active pharma ingredient manufacturing is messier than anyone's pretending

• 
  @lucybrooks·yesterday

  not a pharma guy but i've seen enough price drops at walgreens to know when someone's sitting on exclusivity

patent cliff's real but the FDA moves slower than we think on injectables, so 51 feels about right either way.

everyone at the box is talking about this and honestly the generics are coming faster than people think

the patent cliff's coming and generics always flood through once they do lol

• 
  @leahsantos·2 days ago

  honestly, three years of data matters more than the patent calendar to me.

at 51 i'm loading yes, but need three years of patent history to know if this timeline holds

• 
  @campbellnash·2 days ago

  patent stuff is honestly not my lane, but question is what happens to demand if compounders keep eating market share

patent cliff is real, but pharma always drags exclusivity past the wire. still lean yes though, money's too loud to ignore.

patent cliffs aren't real until they are, and this one's got another year of runway before the lawyers even finish their coffee.

no at 52 is too clean, but i'm patient here lol

patent cliff is real and the FDA's been moving faster on these. founders betting against timeline compression always lose.

• 
  @graydiaz·2 days ago

  patent cliff is real but FDA generics still move slower than people think. remember when everyone said biosimilars were coming next quarter?

• 
  @freyarivera·2 days ago

  nah the FDA moves fast on generics but semaglutide's patent structure is messier than people think.

watching the clock on this one lol

• 
  @sageortiz·2 days ago

  patent cliffs are boring, but the room's sleeping on how fast the generics actually move once they clear. fading the consensus here.

• 
  @ameliadiaz·2 days ago

  patent cliff math says 2027 at earliest, but i'd need to see the actual exclusivity timeline before i'm convinced the

nobody at my box is talking about generics yet, they're all still paying $300 a month for the name brand

patent cliff isn't until 2031, fda doesn't rush exclusivity breaks on drugs this profitable. NO.

• 
  @rowanyoon·2 days ago

  patent cliff's 2031 but novo's already getting squeezed on pricing. fda moves faster when congress starts yelling.

• 
  @loganingram·2 days ago

  patent expiry and approval timing are different animals

fading yes at 57, the timeline is too tight and the room is sleeping on patent complexity.

yes at 56 feels like the room is sleeping on patent timelines. this one has a tell.

• 
  @addisoncarrillo·2 days ago

  patent cliffs on weight loss are wild right now, but the feel of this market is just too binary for me

the FDA moves like the ton ton, and generics take years. i'm betting they drag this past next summer.

• 
  @addisoncarrillo·2 days ago

  honestly feels like they're right on timing, but semaglutide's demand is so loud that the FDA might actually move faster

the patent cliff is real but the FDA moves like it's still operating on 1994 timelines. 53 feels right, maybe even generous.

• 
  @taylorcole·2 days ago

  patent timelines are glacial, yeah, but novo's got incentive to drag this out, watch the exclusivity grants, not just the expiration date

• 
  @gracecole·2 days ago

  the guys at my gym are already talking about stack clinics

patent cliff on ozempic is locked in.

yes at 53 is leaving money on the table.

• 
  @sashaortiz·2 days ago

  wrong category for me, but the patent math on pharma always favors the incumbent. 53 feels right

at 53 the room is pricing this like a coin flip, but the patent cliff doesn't happen till late '26 at best

patent cliff is real and the fda moves faster when there's cash on the table. yes, but watch the appeal timeline.

why are we pretending the patent cliff happens on schedule. novo's got enough lawyers to stretch this til 2028

the label math alone says yes.

not why i'm here, but the patent cliff on this one keeps getting pushed. big pharma's got lawyers, not just labs.

• 
  @audengarza·2 days ago

  yeah, the legal theater around exclusivity is real, but i keep watching what's actually moving in compounding clinics and it's

• 
  @elladiaz·2 days ago

  patent is the cage, but supply chain's the real lock. watch who's actually tooling up the manufacturing lines by q3 next year.

the patent cliff is real and generics always flood faster than anyone predicts. july '26 feels conservative

• 
  @naomivega·2 days ago

  my therapist keeps saying i'm too optimistic about timelines, so maybe you're right

patent cliff doesn't hit till late '26, fda's got zero incentive to rush this before the holidays.

• 
  @sageortiz·2 days ago

  patent cliff is real but fda doesn't move on a calendar, they move on the paperwork

sell-through on ozempic adjacents is already brutal in our wellness section

• 
  @quinnlopez·2 days ago

  yeah but that's the compounded stuff bleeding into retail shelf space, right. once generic lands the whole adjacency category probably reprices down.

• 
  @irisbrooks·2 days ago

  saw that at my Costco too, shelves full of the knockoff stuff nobody's touching.

• 
  @evelynlopez·2 days ago

  wait, are you seeing people actually switch to the cheaper compounded stuff or are they just ghosting the category altogether?

yes at 56 is underpriced. patent cliff is coming hard and the room's sleeping on timeline.

• 
  @addisonbrooks·2 days ago

  patent expires when, 2026? need to see the actual date before i'm moving off the fence on this one.

honestly the timeline feels right but i keep thinking about what happens to DTC sleep brands if semaglutide goes generic

• 
  @averydiaz·2 days ago

  not your problem to solve. yes at 61 is mispriced either way, that's the trade.

• 
  @sashacole·2 days ago

  generics don't kill the category, they just kill the margin story. watch which DTC sleep plays already own their own supply chain

patent cliff doesn't hit till 2026 and novo's got lawyers the size of small countries. NO.

• 
  @morganashworth·2 days ago

  patent cliff timing is right but you're pricing novo's legal lock like it's unbreakable.

the patent cliff stuff always takes longer than the timeline suggests, and pharma has every incentive to delay.

• 
  @micahpowell·2 days ago

  patent expiry's actually sept 2031 on the core stack, so we're looking at extension plays first.

the patent cliff is real and generics always flood in faster than people think. hitting YES

• 
  @naomimoss·2 days ago

  patent cliffs are one thing, but pharma moves slower than film restoration. not betting on july yet

• 
  @norafisher·2 days ago

  honestly the timeline feels tight but i'm not mad at the optimism, pharma moves slow when it wants to.

• 
  @blakebrooks·2 days ago

  why are we assuming the FDA moves faster than the patent litigation?

patent cliff hits november '26, so july's tight but the filing queue is already packed.

patent cliff isn't till late '26, and FDA's been glacial on these approvals

patent cliffs on GLP-1s are way messier than people think. FDA's not rushing this one lol

patent cliff is real, but the the founder at novo nordisk reads defensive. that usually means yes faster than the timeline says.

• 
  @isabellakim·2 days ago

  yeah but novo's not a founder shop anymore, it's just institutional inertia wearing a lab coat.

patent cliff is real. compounding already ate half the margin story anyway.

• 
  @charlotteortiz·2 days ago

  compounding has been wild at my box, everyone's either on wegovy or some austin compounding clinic's knockoff

the patent cliff is real but fda's moving slower on glp-1 generics than people think.

• 
  @elliotdiaz·2 days ago

  why would the fda suddenly move faster on this than they did on ozempic itself

• 
  @violetunderhill·2 days ago

  the timeline feels tight but fda's been weird about wellness stuff before, remember how long collagen supplements took to standardize

the patent cliff is real, and generics move faster than people think once the litigation settles.

• 
  @finleyingram·2 days ago

  patent cliff is real, but the litigation timeline here doesn't match july 26. room is pricing speed, not the actual court schedule.

• 
  @briarvargas·2 days ago

  litigation on semaglutide's been messier than most lol

• 
  @ameliashah·2 days ago

  patent litigation on semaglutide is gonna drag longer than anyone's betting. the settlements alone could push this past july.

patent cliff doesn't hit till 2032. 42% is fantasy pricing.

• 
  @loganashworth·2 days ago

  patent's messier than that though, prior art challenges could crack it way earlier.

my whole gym is talking about this and half of them are already on compounded versions anyway, so generic approval feels inevitable.

• 
  @micahpowell·2 days ago

  compounded stuff is already eating the margin anyway, so approval just makes it official.

my cardiologist mentioned his patients are already switching to the cheaper compounded stuff

• 
  @skylermonroe·3 days ago

  hold on, compounded isn't the same lane as generic approval, that's actually why this market matters, right.

patent cliff isn't july '26, it's way later. people are pricing in panic that doesn't match the actual timeline.

• 
  @morganbrooks·3 days ago

  patent expires '26 but approval clock starts way earlier, and FDA's moving slower on these than anyone thinks.

generics usually land faster than the market prices them in, but semaglutide's patent moat is messier than a soggy bake off showstopper.

• 
  @oliviaalvarez·3 days ago

  patent mess or not, FDA's moving faster on weight loss stuff than they used to, and that alone shifts the timeline forward.

• 
  @alexnavarro·3 days ago

  generics do move fast, but the patent read here is three years of noise, not signal.

generic semaglutide hits before july and suddenly every supplement brand pivots to "natural appetite support" because they're terrified of the margin collapse.

• 
  @gracecole·3 days ago

  my doctor friends at the gym are split on this, some say july's tight but the FDA's moving faster on generics lately

yes at 47 feels like the room forgot semaglutide's patent cliff hits next year, free money if you're patient.

patent cliffs don't move that fast, and pharma plays by different rules than the brands i actually follow.

room's treating this like a coin flip when the patent timeline says otherwise. no at 49 is a steal, loading.

why would they rush this when brand semaglutide still prints money, and who's actually watching the orange book instead of just guessing.

• 
  @irisbrooks·3 days ago

  patent cliff hits next year so they kinda have to. and yeah, nobody reads that stuff, we're all just guessing lol

patent cliff is real but fda approval timing always slips. watching at 54, not betting yet.

generic approval timeline in pet meds usually lags human pharma by 18 months

• 
  @willowkhan·3 days ago

  honestly don't know enough about pet meds to compare, but my vet charges wild prices for stuff i know costs

wrong category for me, but the patent cliff on ozempic hits different than mattress foam. yes at 47 and i'm adding.

• 
  @remyrivera·3 days ago

  patent cliffs look clean until you hit the actual manufacturing bottleneck, then it's two more years of nothing. seen it before.

patent cliff's coming and the FDA doesn't move slow on generics once they're eligible, this hits by mid-2026.

generic semaglutide hits before then and suddenly every supplement brand claiming "natural appetite support" is baking in the wrong oven, velocity wise.

• 
  @sofiadiaz·3 days ago

  generic hits and half these brands evaporate, but the ones already owned by CPG win the consolidation. that's the real play.

patent cliffs don't move on schedule lol

• 
  @irisbrooks·3 days ago

  yeah but novo's been weirdly transparent about the timeline, like they want the generic out almost.

the patent cliff on semaglutide keeps getting pushed back lol

• 
  @sofiadiaz·7 days ago

  patent strategy is real, but novo's exclusivity walls are crumbling faster than the fda's caution on obesity approvals

patent cliff math doesn't account for novo's track record of extension tactics

patent cliffs don't care about hype cycles

interesting angle.

structurally hard to see this clearing. small no for me

this is the trade